At the BIG10 CRC Summit, Mingjia Li, MD, outlined how pre-operative hemoglobin may signal treatment response in resectable NSCLC.
|Videos|April 4, 2019
Targeting the Metastatic Tumor Microenvironment to Limit Cancer Progression
Author(s)Sheila A. Stewart, PhD
Cancer Network spoke with Sheila A. Stewart, PhD, on how age-related changes in the tumor microenvironment may impact progression and metastasis.
Advertisement
Cancer Network spoke with Sheila A. Stewart, PhD, on how age-related changes in the tumor microenvironment may impact progression and metastasis.
Advertisement
Related to this article
Experts highlight KEYNOTE-C93, TroFuse-005, and antibody-drug conjugate data in platinum-resistant ovarian cancer at the ESMO Congress 2026.
Nikolai Strusberg, MD, discussed other toxicities of proton vs photon breast RT, practice implications, and next steps in capsular contracture research.
Nikolai Strusberg, MD, explained the clinical hypothyroidism endpoint and how thyroid dose should guide proton vs photon choice in breast cancer.
Leah Katz, MD, MPH, discusses IDEA, TARGIT-B, NeoORB, and other breast radiation data from ASTRO 2026, and why patient selection is the unifying theme.
Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.
Leah Katz, MD, MPH, explained how an intraoperative tumor bed boost in TARGIT-B may reduce distant relapse in young patients with breast cancer.
Leah Katz, MD, MPH, discusses long-term IDEA trial data on omitting radiation and why endocrine therapy tolerance matters in this decision.
Advertisement
Advertisement
Trending on CancerNetwork
1
The Gynecologic Oncology Data to Watch at ESMO 2026: De-Escalation and ADCs
2
Cancer Vaccine Combinations Improve 1-Year Survival in Second-Line NSCLC
3
Trispecific CAR T Cells Demonstrate Safety, Early Activity in B-Cell Lymphoma
4
The Usefulness of Indocyanine Green in Cytoreductive Ovarian Cancer Surgery
5